Business Context and Reporting Period
This Form 6-K filing by Check-Cap Ltd. (referred to as Mbody AI Ltd. in metadata) covers the period of February 12, 2019. The registrant is a foreign private issuer based in Israel, reporting under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory and operational updates rather than financial performance data.
Material Changes
On February 12, 2019, Check-Cap Ltd. received Institutional Review Board (IRB) approval from the New York University School of Medicine. This approval permits the company to initiate a U.S. pilot study of its C-Scan® system.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future outlook, or a discussion of risks and contingencies. The primary disclosure is the successful regulatory milestone regarding the C-Scan® system pilot study.
Investor Verification Points
- Verify the scope and timeline of the U.S. pilot study for the C-Scan® system at New York University School of Medicine.
- Confirm the status of the Post-Effective Amendment No. 1 to Form S-8 and the referenced Form F-3 Registration Statements.
- Review the attached press release (Exhibit 99.1) for detailed technical specifications of the pilot study.